Background-Previous studies suggest that transforming growth factor-␤ provokes cardiac hypertrophy and myocardial fibrosis; however, it is unclear whether the deleterious effects of transforming growth factor-␤ signaling are conveyed through SMAD-dependent or SMAD-independent signaling pathways. Methods and Results-To determine the contribution of SMAD-dependent signaling to cardiac remodeling, we performed transaortic constriction in SMAD3 null (SMAD3 Ϫ/Ϫ ) and littermate control mice (age, 10 to 12 weeks). Cumulative survival 20 days after transaortic constriction was significantly less in the SMAD3 Ϫ/Ϫ mice when compared with littermate controls (43.6% versus 90.9%, PϽ0.01). Transaortic constriction resulted in a significant increase in cardiac hypertrophy in the SMAD3 Ϫ/Ϫ mice, denoted by an increase in the heart weight to tibial length ratio and increased myocyte cross-sectional area. Loss of SMAD3 signaling also resulted in a significant 60% decrease in myocardial fibrosis (PϽ0.05). A microRNA microarray showed that 55 microRNAs were differentially expressed in littermate and SMAD3 Ϫ/Ϫ mice and that 10 of these microRNAs were predicted to bind to genes that regulate the extracellular matrix. Of these 10 candidate microRNAs, both miR-25 and miR-29a were sufficient to decrease collagen gene expression when transfected into isolated cardiac fibroblasts in vitro.
M embers of the transforming growth factor (TGF)-␤ superfamily are multifunctional cytokines that play an important role in cell growth, differentiation, and tissue repair in a variety of organs, including the heart. 1, 2 The TGF-␤ superfamily can be broadly divided into 2 major groups: the TGF-␤/activin subfamily and the bone morphogenic protein (BMP)/growth and differentiation (GDF) subfamily. TGF-␤ family members exert their effects by binding to heterodimeric cell surface receptors, consisting of membrane bound type I serine/threonine receptor kinases (activin-like kinases [ALK] 1 to 7) and membrane bound type II serine/ threonine receptor kinases (T␤RII, ActRII, ActRIIB, BMP-RII, and AMHR). 3 After a ligand/type I/type II receptor complex is formed, the constitutively activated type II receptor transphosphorylates and activates the type I receptor, which in turn phosphorylates downstream cytoplasmic mediators belonging to the SMAD family (for mammalian homologue of Sma proteins in Caenorhabditis elegans and mothers against decapentaplegic [MAD] proteins in Drosophila). 3, 4 Members of the SMAD family of proteins fall into 3 structurally and functionally distinct groups: receptor SMADs (SMADs 1, 2, 3, 5, and 8), comediator SMAD (SMAD 4), and the inhibitory SMADs (SMADs 6 and 7). All 3 functional classes of SMADs and the majority of SMAD isoforms have been detected in the cardiovascular system. 2 TGF-␤ family members can also signal in a SMADindependent manner through the activation of TGF-␤induced kinase-1 (TAK1), mitogen-activated protein kinases, -kinases, and Akt. 1, 3, 5 
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Previous studies suggest that the TGF-␤/activin and BMP/ GDF family members exert distinct effects in the heart. That is, although TGF-␤ family members predominately mediate deleterious effects in the adult heart, including cardiac hypertrophy and myocardial fibrosis, 6 -11 BMP family members are essential for heart development and promote differentiation of cardiac myocytes. This diversity of effects is thought to arise, at least in part, secondary to the variety of signaling pathways that are activated by members of the TGF-␤ superfamily. For example, TGF-␤, which binds to a complex of T␤RII and ALK5, results in the activation of SMADs 2 and 3, whereas BMP binds to BMPR-II and ALK2, -3, or -6 and activates SMADs 1, 5, or 8. What remains unclear, however, is whether the deleterious effects of TGF-␤ signaling are conveyed through SMAD-dependent 2 or SMADindependent signaling pathways. 12 Accordingly, to determine the contribution of SMAD3-dependent signaling to cardiac remodeling, we subjected SMAD3-deficient mice to transverse aortic constriction (TAC). We show that loss of SMAD3dependent signaling results in increased pressure overloadinduced myocardial fibrosis that is accompanied by the differential expression of 2 microRNAs (miR-25 and miR-29a) in vivo, which are sufficient to decrease collagen gene expression in isolated cardiac fibroblasts in vitro, thus providing a potentially novel mechanism for SMAD3-mediated fibrosis. We also show that loss of SMAD3-mediated signaling results in increased mortality and increased concentric cardiac hypertrophy, suggesting that SMAD3-mediated signaling is cardioprotective after hemodynamic pressure overloading.
Methods

Generation of SMAD3-Deficient Mice
The SMAD3-deficient mice used herein were generated by targeted disruption of exon 8 of the SMAD3 gene and were the generous gift of Dr Anita Roberts. The cardiac phenotype of these mice has been reported elsewhere. 13 Heterozygous mice (SMAD3 ϩ/Ϫ ) on a C57BL/6J background were backcrossed to generate mice that were null for SMAD3 (SMAD3 Ϫ/Ϫ ). Littermates with both SMAD3 alleles intact (SMAD3 ϩ/ϩ ) were used as the appropriate controls. All mice were housed under standard environmental conditions and were fed commercial chow and tap water ad libitum. All studies conformed with the principles of the National Institutes of Health "Guide for the Care and Use of Laboratory Animals" and were approved by the Baylor College of Medicine Animal Care and Use Committee.
Effect of Pressure Overload on Survival in SMAD3 ؊/؊ Mice
Transverse Aortic Constriction
Hemodynamic pressure overloading was achieved by transverse aortic constriction (TAC) in 10-to 12-week-old male and female SMAD3 Ϫ/Ϫ and littermate control mice, exactly as described. 14 To ensure that the mice were subjected to a significant hemodynamic pressure overload, we used a 20-MHz pulsed Doppler probe coupled to a fast-Fourier transform spectrum analyzer (model SP-25A, Medasonics, Newark, Calif) to record flow velocity in the right and left carotid arteries at 24 to 48 hours after TAC. For the studies reported herein, we only used mice that had Doppler flow velocity ratios Ͼ5:1. Previously, we have shown that this degree of hemodynamic pressure overload leads to significant increase in cardiac hypertrophy, without a significant increase in morbidity and mortality. 14 Sham-operated SMAD3 Ϫ/Ϫ and littermates were used as the appropriate controls. Mice were euthanized on days 10 and 20 after TAC, and the hearts were perfusion fixed in a formaldehyde-zinc buffer (Z-fix, Anatech, Ltd, Battlecreek, Mich) for a histological analysis. At the time of terminal killing, the mice were observed for signs of volume overload (pleural effusions and/or pericardial effusions). Wet and dry lung weights were measured at baseline and 20 days after banding to determine the wet-to-dry lung ratio for each mouse. Dry lung weights were measured after desiccating the lungs in a convection oven at 55°C for 3 hours. We also attempted to measure ambulatory heart rate monitoring in the littermate control and SMAD3 Ϫ/Ϫ mice. However, because of their relatively smaller body weights, the SMAD3 Ϫ/Ϫ mice failed to thrive or died after implantation of the telemetry devices (TA10EA-F20, Datasciences, Minneapolis, Minn). As a result, the Baylor Animal Use and Care Committee requested that we discontinue implantation of the telemetry devices in the SMAD3 null mice.
Effect of Pressure Overload on Cardiac Structure in SMAD3 ؊/؊ Mice
Cardiac Hypertrophy
Cardiac hypertrophy was assessed by determining the heart weight to tibial length (HW/TL) ratio heart weight to body weight ratios in littermate control and SMAD Ϫ/Ϫ mice at baseline and 10 and 20 days after TAC. 15 Cardiac myocyte cross-sectional area was determined at identical time points using lectin staining, exactly as described. 16 A minimum of 100 myocytes from each heart were examined at midmyocardial levels under ϫ400 magnification.
Two-dimensional-targeted M-mode echocardiography was used to measure left ventricular (LV) structure after hemodynamic overloading, as described. 14 Images were obtained at baseline and days 10 and 20 in the banded and sham-operated animals. Anesthesia was induced using 1% isoflurane and was maintained using 0.5% isoflurane. Throughout the 2D echocardiographic studies, care was taken to maintain the heart rateϾ400 bpm by adjusting the level of anesthesia. All 2D and M-mode echocardiographic measurements were performed by an investigator who was blinded to the experimental group that being studied.
Myocardial Fibrosis
Perfusion-fixed hearts from SMAD3 Ϫ/Ϫ and littermate control mice obtained at baseline and days 10 and 20 after TAC or sham operation were embedded in paraffin and stained using the picrosirius red technique, as described. 17 To calculate the extent of myocardial fibrosis, the LV was divided into 8 quadrants, and the percent area of extracellular picrosirius red staining was computed from random images obtained in each quadrant. Large epicardial arteries and/or veins were excluded, as well as any cutting and/or compression artifacts. At least 16 to 24 measurements were made for each heart from each group being studied.
Effect of Pressure Overload on Myocardial Inflammation in SMAD3 ؊/؊ Mice
To determine whether hemodynamic pressure overloading resulted in increased myocardial inflammation in the SMAD3 Ϫ/Ϫ mice, the hearts were perfusion fixed at baseline and on days 10 and 20 after TAC, as described earlier. Transverse myocardial sections were stained with hematoxylin and eosin and were observed by a light microscopy at ϫ200 magnification for the degree of cellular infiltration. Three to 4 axial cross-sections from each heart at the midpapillary level were identified, and each section was divided into quadrants and examined by an independent investigator in a blinded manner. The degree of myocardial inflammation was scored semiquantitatively in the following manner: 0, no infiltrate; 1ϩ, infiltrates involving Ͻ25% of the myocardium; 2ϩ, infiltrates involving 25% to 50% of the myocardium; 3, infiltrates involving 50% to 75% of the myocardium; and 4ϩ, infiltrates involving 75% to 100% of the myocardium, as described by Kanda et al. 18 
Role of MicroRNAs in Myocardial Fibrosis
Analysis of MicroRNA Expression in SMAD3 ؊/؊ Mice
To determine whether microRNAs that target genes that regulate the extracellular matrix were expressed differentially in the littermate control and SMAD3 Ϫ/Ϫ mice after TAC, we performed a microRNA microarray. Total RNA was extracted from the hearts of SMAD3 Ϫ/Ϫ and littermate control mice 10 days after sham operation or TAC, using TRIzol reagent (Invitrogen, Carlsbad, Calif). The manufacturer's protocol was modified for the enrichment of small RNAs by overnight precipitation using excess volume of isopropyl alcohol (1.5ϫ TRIzol volume), at Ϫ80°C. One hundred micrograms of RNA were sent to L.C. sciences for microRNA microarray. 19 RNA from shamoperated littermate control and SMAD3 Ϫ/Ϫ mice and littermate control and SMAD3 Ϫ/Ϫ mice exposed to TAC was labeled with Cy3 and Cy5 fluorescent dyes, and each pair of samples was hybridized to a single chip that held 380 mature microRNA probes that are listed in Sanger miRBase Release 9.2 (http://www.sanger.ac.uk/Software/ Rfam/mirna/) along with control probes used for standardization and quality control. Signal intensities from the array output were normalized after background subtraction using preset control probe intensities. MicroRNAs that were differentially expressed (PϽ0.01 by ANOVA) were identified, and candidate microRNAs that were predicted to control fibrosis-related genes (see Results) were selected for further experiments.
Validation of MicroRNA Targets
To determine whether the microRNAs identified in the microarray affected collagen gene expression, we transfected selected microRNAs (see Results) into cardiac fibroblasts and then examined Collagen I and Collagen III gene expressions using quantitative RT-PCR. Briefly, mouse cardiac fibroblasts were prepared as previously described from hearts of 9-to 12-week-old C57BL/6 mice. Cells from passages 3 to 5 were cultured in DMEM containing 10% FBS but without antibiotics. Twenty-four hours after plating, the cells were treated with synthetic microRNAs (20 to 50 pM) that were designed to mimic endogenous precursor microRNAs (pre-miRs, Ambion, Inc, Foster City, Calif). Transfection was carried out according to manufacturer's protocol in serum-free media using lipofectamine 2000 (Invitrogen, Inc). To confirm transfection of microRNAs into the cardiac fibroblasts, we used a Cy3-labeled pre-miR negative control (catalog No. AM17120, Ambion, Inc), a nontargeting microRNA tagged at 5Ј end with a Cy3 fluorophor. To determine the transfection efficiency, we examined the expression levels of the Cy3-tagged microRNAs by immunoflorescence in fibroblast cultures at 6, 24, 48, and 72 hours after transfection. In preliminary control experiments, we determined that a concentration of 30 pM of oligonucleotide and 2 L lipofectamine per milliliter of culture medium resulted in minimum cell toxicity and maximum transfection efficiency (98% efficiency). After optimization, transfection was carried out using pre-miR precursors of selected microRNAs or unlabeled pre-miR microRNA precursor negative control (Cat#AM17110, Ambion Inc).
Collagen I (COL1A1 and COL1A2) and Collagen III (COL3A1) gene expressions were determined using RT-PCR. Briefly, total RNA was isolated from cardiac fibroblasts 48 hours after transfection, using TRIzol reagent (Invitrogen, Carlsbad, Calif). One microgram of RNA was converted to cDNA using a high-capacity cDNA reverse transcription kit with random hexamers (Applied Biosystems, Foster City, Calif). The primers for COL1A1, COL1A2, and COL3A1 and their corresponding FAM-labeled TaqMan MGB probes (TaqMan gene expression assays, Applied Biosystems) were used to perform RT-PCR of the cDNA samples on an ABI 7300 RT-PCR system (Applied Biosystems). The 18S ribosomal RNA was used as a RNA loading control, and expression levels of target genes in samples were normalized to a control sample using the comparative Ct ([Delta][Delta]Ct) method as described earlier. 20 
Statistical Analysis
Each value is expressed as meanϮSEM. Survival of SMAD3 and littermate mice were compared using the Kaplan-Meier method. Two-way ANOVA was used to test for mean differences in wet-todry lung weight ratios, cardiac hypertrophy, heart weight, body weight, HW/TL ratios, heart weight to body weight ratios, left ventricular wall thickness, radius to height ratio, LV internal diastolic dimension, fractional shortening, fibrillar collagen content, myocardial inflammatory scores, and Mac-2 ϩ cell counts in the SMAD3 and littermate mice at baseline and on days 10 and 20 after aortic banding. Doppler flow velocity ratios between right and left carotid arteries were compared in the SMAD3 and littermate mice using t test. Where appropriate, post hoc ANOVA testing (protected least significant difference test) was used to assess the mean differences between groups at a given time point. Significant differences were said to exist at a value of PϽ0.05. Figure 1A depicts the Kaplan-Meier analysis for the littermate control mice and SMAD3 Ϫ/Ϫ mice after TAC. As shown, the cumulative survival at 20 days after TAC was significantly less in the SMAD3 Ϫ/Ϫ mice when compared with littermate controls (43.6% versus 90.9%, PϽ0.01). Importantly, there were no deaths in the littermate control or SMAD3 Ϫ/Ϫ mice that underwent sham surgery. Inspection of the Kaplan-Meier curves showed that the deaths in the SMAD3 Ϫ/Ϫ mice began several days after surgery and continued throughout the 20-day time of observation. To determine the potential mechanism(s) for the increased mortality in the SMAD3 Ϫ/Ϫ mice after TAC, we examined the mice for pleural and/or pericardial effusions at the time of terminal killing or after sudden death. This analysis disclosed that there was no evidence of pericardial or pleural effusions in the SMAD3 Ϫ/Ϫ mice. We also examined the wet-to-dry lung ratio in the littermate control mice and the SMAD3 Ϫ/Ϫ mice at baseline and 20 days after TAC. Although there was a small but statistically significant (PϽ0.05) increase in the wet-to-dry lung ratio in both groups of mice after TAC ( Figure 1B) , there was no significant increase in the wet-todry lung ratio in the SMAD3 Ϫ/Ϫ mice when compared with the littermate control mice after TAC (PϾ0.05). Taken together, these observations suggest that heart failure was unlikely to be the proximate cause of the increase in mortality in the pressure-overloaded SMAD3 Ϫ/Ϫ mice. As noted earlier, it was not possible to implant telemetry devices in the SMAD3 Ϫ/Ϫ mice; therefore, we could not determine whether the increase in mortality in the SMAD3 Ϫ/Ϫ mice was secondary to brady-or tachyarrhythmias.
Results
Effect of Pressure Overload on Survival in SMAD3 ؊/؊ Mice
Effect of Pressure Overload on Cardiac Structure in SMAD3 ؊/؊ Mice
Cardiac Hypertrophy
A morphological examination of transverse sections of the heart at the midpapillary level at baseline and 10 and 20 days after TAC revealed that both littermate control and SMAD3 Ϫ/Ϫ mice developed concentric hypertrophy after banding. However, the salient finding shown by Figure 2 is that the degree of cardiac hypertrophy was significantly greater in the SMAD3 Ϫ/Ϫ mice on days 10 and 20 after TAC when compared with littermate control mice. Figure   2B shows that although the HW/TL ratio were similar in the SMAD3-deficient mice at baseline, the HW/TL ratio was significantly greater in the SMAD3 Ϫ/Ϫ mice by days 10 (PϽ0.05) and 20 (PϽ0.05) after TAC. Similar results were obtained when heart weight to body weight ratios were determined (Table 1) . Two-dimensional echocardiographic analysis ( Figure 2C ) of SMAD3 Ϫ/Ϫ and littermate control mice showed that LV wall thickness was increased significantly in the SMAD3 Ϫ/Ϫ mice on days 10 and 20 after TAC (PϽ0.05), and the radius to height ratio was decreased significantly (PϽ0.05) in the SMAD3 Ϫ/Ϫ mice on day 20 after TAC, consistent with a greater degree of concentric hypertrophy in the SMAD3 null mice ( Figure  2C and 2D ). There were neither significant differences in the LV end-diastolic dimension nor fractional shortening in SMAD3 Ϫ/Ϫ mice relative to littermate control mice after TAC ( Table 2) .
To determine whether the increase in cardiac hypertrophy in the SMAD-deficient mice was secondary to an increase in cardiac myocyte cell size, we also examined myocyte crosssectional area using lectin staining. As shown in Figure 2E , the myocyte cross-sectional area at baseline was significantly lower in SMAD3 Ϫ/Ϫ mice compared with littermates, consistent with the lower HW/TL ratios at baseline. However, the cross-sectional area of the myocytes in the SMAD3 Ϫ/Ϫ mice was significantly (PϽ0.01) greater 20 days after TAC when compared with littermate controls. Taken together, these results suggest that SMAD3 signaling negatively modulates cardiac hypertrophic growth after hemodynamic pressure overloading.
Myocardial Fibrosis
To determine whether SMAD3 significantly contributed to the increase in myocardial fibrosis that is observed after hemodynamic pressure overloading, we assessed collagen content in SMAD3 Ϫ/Ϫ mice at 10 and 20 days after TAC using the picrosirius red technique. Figure 3A depicts representative pircosirius red-stained myocardial sections of littermate control and SMAD3 null mice at baseline and on days 10 and 20 after TAC, whereas Figure 3B summarizes the results of group data. As shown in Figure 3B , the percent area of the LV that stained positively with picrosirius red in-creased in both the littermate control and SMAD3 null mice on days 10 and 20 after TAC, consistent with the known effects of pressure overload on myocardial fibrosis. Although there was a significant overall increase in myocardial fibrosis in the littermate control mice (PϽ0.05 by ANOVA), the increase in fibrosis was not statistically significant in the SMAD3 null mice (PϾ0.05 by ANOVA). Importantly, the extent of picrosirius red staining was significantly less in the SMAD null mice compared with littermate control mice on days 10 and 20 after TAC.
Effect of Pressure Overload on Myocardial Inflammation in SMAD3 ؊/؊ Mice
Insofar, as TGF-␤ suppresses inflammation, we asked whether the cardiac hypertrophic phenotype and/or decreased survival in the SMAD3 Ϫ/Ϫ mice was secondary to increased myocardial inflammation. Figure 4A shows representative hematoxylin and eosin-stained sections at baseline and on day 10 after TAC, and Figure 4B summarizes the results of group data. Although there was a significant increase in the inflammatory infiltrate in both the littermate control and the SMAD3-deficient mice at 10 and 20 days after TAC when compared with baseline (Pϭ0.02 by ANOVA), there was no significant difference in the inflammatory infiltrate score between the littermate controls and SMAD3 Ϫ/Ϫ mice on either day 10 (Pϭ0.51) or day 20 (Pϭ0.64) after TAC.
Role of MicroRNAs in Myocardial Fibrosis
Analysis of MicroRNA Expression in SMAD3 ؊/؊ Mice
Recent studies have uncovered a potentially important role for a family of tiny regulatory RNAs, known as microRNAs (miRNAs or miRs), in the control of cardiac remodeling and myocardial fibrosis (reviewed in Ref. 21 ). Insofar, as recent studies suggest that SMAD-dependent signaling governs the processing of mature microRNAs, 22 we performed a mi-croRNA microarray analysis in sham-operated and banded (day 10) littermate control and SMAD3 Ϫ/Ϫ mice. The changes in the expression levels of microRNAs in SMAD3 Ϫ/Ϫ banded, SMAD3 Ϫ/Ϫ sham-operated, littermate banded, and littermate sham-operated mice were considered to be statistically significant at the PϽ0.01 level. As shown by the heat map in Figure 5A , there were 55 microRNAs that were differentially expressed in banded littermate control and SMAD3 Ϫ/Ϫ mice compared with sham-operated littermate control and SMAD3 Ϫ/Ϫ control mice (PϽ0.05 by ANOVA). Specifically, 19 microRNAs were upregulated and 18 mi- Two-dimensional echocardiographic analysis of littermate control and SMAD3 Ϫ/Ϫ mice (nϭ3 to 8 mice per group per time) was performed at baseline and 10 and 20 days after TAC. There was no significant difference in the LVEDD and the % FS between the groups of mice (all P values are nonsignificant; nϭ3 or more mice per group per time point). FS indicates fractional shortening; LVEDD, left ventricular end-diastolic dimension; TAC, transaortic constriction. 
Selection of Candidate miRNAs
To determine whether any of the 55 miRNAs that were differentially expressed may have contributed to the decreased myocardial fibrosis observed in SMAD3 Ϫ/Ϫ mice, we first generated a list of 28 potential genes ( Figure 5B ) that have been implicated in the development of myocardial fibrosis, based on a review of the extant literature. [23] [24] [25] [26] For the 28 potential gene targets, we then cross-referenced known or predicted miRNA interactions for these genes using 3 target-prediction algorithms: (i) Targetscan (http:// www.targetscan.org), (ii) miRbase (http://micronrna. sanger.ac.uk), and (iii) PicTar (http://pictar.bio.nyu.edu). As shown by Figure 5D , there were 10 candidate microRNAs that were significantly upregulated or downregulated in the banded SMAD3 Ϫ/Ϫ mice and/or littermate control mice (relative to sham-operated mice) that were predicted to bind to genes that regulate the extracellular cellular matrix. Of these 10 candidate microRNAs, 5 microRNAs had 4 or more predicted targets, of which miR-25 and miR-29a had the most predicted extracellular cellular matrix targets (we did not include Let-7d* because of low expression levels in cardiac tissue). As shown in the online Data Supplement, miR-25 was decreased by 40% in the banded littermate control mice and increased 15% in the banded SMAD3 Ϫ/Ϫ mice relative to their respective sham-operated controls, whereas miR-29a was decreased 8% in the banded littermate controls and decreased 36% in the banded SMAD3 Ϫ/Ϫ mice relative to sham-operated mice. On the basis of the number of predicted extracellular cellular matrix gene targets for these 2 microRNAs, as well as the differential expression of miR-25 and miR-29a in littermate control and SMAD3 null mice, we selected to study the effects of these 2 miRs in isolated cardiac fibroblasts.
Effects of miR-25 and miR-29a on Collagen mRNA Levels
The accumulation of collagen in the interstitium is secondary to an imbalance between collagen synthesis and degradation. The predominant collagens in the heart are types I, III, and IV, of which types I and III are almost exclusively secreted by cardiac fibroblasts. Type I collagen is composed of 2 ␣-1 chains and 1 ␣-2 chain, the product of collagen genes COL1A1 and COL1A2, respectively. Type III collagen is comprised of 2 ␣-1 chains from COL3A1 gene. 27 Figure 6A through 6C depicts representative photomicrographs of Cy3tagged pre-miR microRNAs that were transfected into cardiac fibroblasts (48 hours) and show that the microRNAs were predominately localized in the cytoplasm of the cardiac fibroblasts. As shown in Figure 6D , transfection of pre-miR-25 and pre-miR-29a resulted in decreased Collagen I (COL1A1 and COL1A2) and Collagen III (COL3A1) gene expression at 48 hours. The changes in COL1A2 gene expression were statistically significant (PϽ0.05) for miR-25 and miR-29a, whereas miR-29a resulted in significantly (PϽ0.05) decreased expression of COL1A1 and COL3A1 mRNA levels. Importantly, transfection of a pre-miR negative control had no effect on COL1A1, COL1A2, or COL3A1 mRNA levels.
Discussion
The study, in which we examined the effects of TAC in SMAD3 null mice (SMAD3 Ϫ/Ϫ ), suggests that SMAD3 signaling plays both beneficial and deleterious roles in the heart in response to superimposed hemodynamic pressure overloading. Three major lines of evidence support this statement. First, there was a significant and striking increase in mortality in the SMAD3 Ϫ/Ϫ mice after TAC ( Figure 1A) . Although the mechanism for the increase in mortality in the SMAD3 Ϫ/Ϫ mice was not determined, it was likely related to an arrhythmia because there was no evidence of increased pulmonary congestion ( Figure 1B ), systemic congestion, or LV dysfunction (Table 2) in the SMAD3 Ϫ/Ϫ mice. Second, there was a significant increase in concentric hypertrophy in the SMAD3 Ϫ/Ϫ mice, as shown by the increase in the HW/TL ratio ( Figure 2B ), increased LV wall thickness ( Figure 2C ), decreased LV radius to LV wall thickness ratio ( Figure 2D ), and increased myocyte cross-sectional area in these mice. Third, there was a significant decrease in myocardial fibrosis in the SMAD3 Ϫ/Ϫ mice, consistent with the known role of SMAD3 in modulating fibrosis. 13,28 -32 The decrease in myocardial fibrosis in the SMAD3 null mice was not secondary to decreased inflammation, in that the inflammatory scores were overlapping in the SMAD3 Ϫ/Ϫ mice and littermate control mice ( Figure 4D) .
Given the recent insight that SMAD-dependent signaling regulates the processing of mature microRNAs, 22 as well as the role that microRNAs play in modulating stress signals in the heart, 21 including the regulation of myocardial fibrosis, we performed a microarray analysis of microRNAs in the littermate control and SMAD3 Ϫ/Ϫ mice with the intent of identifying microRNAs that targeted genes that govern remodeling of the extracellular matrix. As shown in Figure 5D , there were 10 "candidate" microRNAs that were differentially regulated in the banded littermate control and SMAD3 Ϫ/Ϫ mice that were predicted to bind to genes that regulate the extracellular matrix, including miR-25, -29a, -101a, -199a, -148a, -214, -224, -499, -705, and Let-7d. Transfection of 2 of these candidate microRNAs (miR-25 and miR-29a) that had COL1 and COL3 as predicted gene targets resulted in decreased collagen gene expression in isolated cardiac fibroblasts in vitro. Of note, miR-29a has been shown to be upregulated in experimental and clinical models of heart failure 33 and downregulated in the border zones of infarcts in mice. 34 Further in vivo studies will be necessary to confirm the role of miR-25 and miR-29a in terms of mediating SMAD3-dependent fibrosis in the adult heart. Viewed together, these results suggest that SMAD3 signaling plays a beneficial role in the heart by delimiting hypertrophic growth and conferring cytoprotection, as well as a deleterious role by modulating myocardial fibrosis.
SMAD3 Signaling in the Heart
The decreased pressure overload-induced fibrosis in the SMAD3 Ϫ/Ϫ mice relative to banded littermate control mice (Figure 3) is consistent with previous studies that have shown decreased fibrosis in SMAD3 null mice after acute myocardial infarction, 13 bleomycin-induced lung injury, 28 vascular injury, 29, 30 ␥-radiation injury, 31 and CC1 4 -induced hepatic injury. 32 With that said, the results of this study expand on previous studies by demonstrating that several microRNAs, including miR-25, -29a, -499, -705, -224, -199a, and -148, are differentially regulated in the SMAD3 null mice relative to littermate controls after TAC. Our findings with respect to decreased relative expression levels of miR-29a in the banded SMAD3 null mice are consistent with the recent findings reported by van Rooij et al, 34 who observed that both miR-29a and miR-29b were downregulated in the border zone infarcts in mice, and that downregulation of miR-29b with anti-miRs induced collagen expression both in vitro and in vivo, whereas overexpression of a miR-29b mimic in isolated cardiac fibroblasts reduced collagen transcripts. They further reported that stimulation of isolated cardiac fibroblasts with TGF-␤ significantly decreased miR-29a-c expression. Our results confirm and expand on these important findings in 2 ways. First, our data suggest that SMAD3dependent signaling may be responsible for "fine tuning" the expression levels of different profibrotic microRNA transcripts. Indeed, our data show that the changes in miR-29 expression levels in the banded SMAD3 Ϫ/Ϫ mice were greater for miR-29a (PϽ0.007) than for miR-29c (PϽ0.06) and miR-29b (PϽ0. 22) . Given that both miR-29a and miR-29b are coexpressed as part of the same bicistronic unit, it is possible that SMAD-dependent signaling may allow for the differential expression of 1 or more profibrotic microRNAs at different times. In this regard, it is interesting to note that SMAD-dependent signaling has recently been shown to lead to increased levels of mature microRNAs by interacting with the DROSHA microprocessor complex. 22 Accordingly, in future studies, it will be important to determine whether the changes in the expression levels of the profibrotic microRNAs identified in this study are regulated by SMAD-dependent interaction with the DROSHA processing complex (eg, through inhibitory microRNAs). Second, our data suggest that multiple microRNAs are likely involved in fibrosis, either singly or in combination. For example, our data suggest a potential inhibitory role for miR-25 in terms of COL1A2, which was not identified in the screen by van Rooij et al. The observation that the relative expression levels of miR-25 were increased in the banded SMAD3 Ϫ/Ϫ mice suggests that the effects of miR-25 are either indirect or the result of suppression of an inhibitory microRNA.
Although the focus of this study was on delineating the role of SMAD3-dependent signaling on myocardial fibrosis and pathological remodeling, the observed increase in pressure overload-induced hypertrophic growth in the SMAD3 null mice ( Figure 2 ) warrants further discussion, particularly in view the plethora of studies that have suggested an important role for TGF-␤ signaling in terms of mediating hypertrophic growth in the heart. 6 -11 This statement notwithstanding, the results of this study are consistent with 2 recent lines of evidence, which suggest that SMAD-dependent signaling inhibits rather than stimulates hypertrophic growth in the mammalian heart. First, recent studies of growth and differentiation factor 15 (GDF15), a 12-kDa secreted protein that signals through SMAD2/3 in the heart, 5 show that mice with cardiac-restricted overexpression of GDF15 were partially resistant to pressure overload-induced hypertrophy, whereas GDF15 gene-targeted mice showed enhanced cardiac hypertrophic growth after superimposition of a hemodynamic pressure overload. 5 Second, cardiac-restricted deletion of SMAD4 (which would inhibit SMADs 1, 2, 3, 6, 8 signaling) resulted in increased cardiac hypertrophy, decreased contractility, and increased mortality, 35 consistent with that point of view that SMAD-dependent pathways inhibit hypertrophic growth in the heart. Last, it should be recognized that the results of this and previous studies 5, 35 are consistent with the observation that SMAD-dependent signaling is growth inhibitory in nonmyocyte cell types, and that loss of SMADdependent signaling results in tumorigenesis. 36, 37 
Conclusions
In summary, the results of this study suggest that SMAD3mediated signaling plays dual roles in the heart: one that is beneficial, by delimiting hypertrophic growth and providing cardioprotective response in the heart after hemodynamic overloading, and a second role that is maladaptive, by mediating progressive myocardial fibrosis that can lead to increased myocardial stiffness, contractile dysfunction, and increased cardiac arrhythmias. Given that SMAD-dependent signaling is highly conserved in nature 38 and has been observed in both vertebrates and invertebrate species, the provocative question that arises from these conflicting observations is why nature has retained both adaptive and maladaptive pathways in the adult mammalian heart? Although the immediate answer to this important question is not obvious, one potential explanation (albeit speculative) is that cross-talk between the SMAD-dependent and SMADindependent signaling pathways may ultimately determine whether signaling by the TGF-␤ superfamily of ligands becomes adaptive or maladaptive in the heart. That is, whereas the immediate role for TGF-␤ signaling is to confer cytoprotective responses and to delimit hypertrophic growth, sustained signaling through SMAD-dependent and SMADindependent signaling results in myocardial fibrosis and hypertrophic growth, respectively. In this regard, it will be also interesting to determine whether SMAD-induced accumulation of 1 or more microRNAs in the heart contributes to the transition from adaptive hypertrophy to decompensated cardiac failure.
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